Literature DB >> 9873951

Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma.

W E Fisher1, P Muscarella, L G Boros, W J Schirmer.   

Abstract

CONCLUSION: Gastrointestinal hormones and their antagonists can alter the growth of pancreatic adenocarcinoma in vitro and in vivo. The potential clinical benefit of this approach deserves further study.
BACKGROUND: Epithelial cell growth is normally under hormonal control. Hormones also affect the growth of many epithelial cancers, and this fact is used to modify tumor growth. Pancreatic epithelial cell growth is under the influence of gastrointestinal hormones. This article reviews experiments designed to determine the effect of gastrointestinal hormones on the growth of pancreatic adenocarcinoma.
METHODS: Eighty-eight articles were identified from a Medline search using the terms pancreatic adenocarcinoma and the individual names of gastrointestinal hormones. The experimental design and results of these studies are reviewed.
RESULTS: In general, somatostatin, vasoactive intestinal polypeptide, pancreatic polypeptide, and pancreastatin inhibit pancreatic adenocarcinoma growth. Cholecystokinin, secretin, bombesin, gastrin, EGF, TGF-alpha, insulin, and IGF-1 have a growth-promoting effect.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9873951     DOI: 10.1007/BF02788419

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  75 in total

1.  Response to exogenous cholecystokinin of six human gastrointestinal cancers xenografted in nude mice.

Authors:  C Hudd; M C LaRegina; J E Devine; D C Palmer; D R Herbold; M C Beinfeld; F B Gelder; F E Johnson
Journal:  Am J Surg       Date:  1989-04       Impact factor: 2.565

2.  Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle.

Authors:  J J Smith; R Derynck; M Korc
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

3.  Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion.

Authors:  K Tatemoto; S Efendić; V Mutt; G Makk; G J Feistner; J D Barchas
Journal:  Nature       Date:  1986 Dec 4-10       Impact factor: 49.962

4.  Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.

Authors:  K Szepeshazi; A V Schally; R Z Cai; S Radulovic; S Milovanovic; B Szoke
Journal:  Cancer Res       Date:  1991-11-01       Impact factor: 12.701

5.  A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer.

Authors:  J L Abbruzzese; C F Gholson; K Daugherty; E Larson; R DuBrow; R Berlin; B Levin
Journal:  Pancreas       Date:  1992       Impact factor: 3.327

6.  Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). The French Associations for Surgical Research.

Authors:  M Huguier; G Samama; J Testart; S Mauban; A Fingerhut; J Nassar; S Houry; D Jaeck; P De Mestier; J P Favre
Journal:  Am J Surg       Date:  1992-10       Impact factor: 2.565

7.  Treatment with secretin and a cholecystokinin-like peptide in patients with pancreatic cancer. A pilot study.

Authors:  S Steffensrud; H Erichsen; P Røysland; T B Halvorsen; R Klepp; O Klepp; E Wünsch; H Petersen
Journal:  Scand J Gastroenterol       Date:  1984-10       Impact factor: 2.423

8.  Cholecystokinin receptors and PANC-1 human pancreatic cancer cells.

Authors:  J P Smith; C A Rickabaugh; P J McLaughlin; I S Zagon
Journal:  Am J Physiol       Date:  1993-07

Review 9.  Hormone receptors. An update and application.

Authors:  C A Hubay; B Arafah; N H Gordon; S P Guyton; J P Crowe
Journal:  Surg Clin North Am       Date:  1984-12       Impact factor: 2.741

10.  Role of cholecystokinin in dietary fat-promoted azaserine-induced pancreatic carcinogenesis in rats.

Authors:  M J Appel; M Meijers; A Van Garderen-Hoetmer; C B Lamers; L C Rovati; D Sprij-Mooij; J B Jansen; R A Woutersen
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

View more
  3 in total

Review 1.  Defining the cancer master switch.

Authors:  Courtney J Balentine; David H Berger; Shi-He Liu; Changyi Chen; John Nemunaitis; F Charles Brunicardi
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

2.  Gut peptide receptor expression in human pancreatic cancers.

Authors:  R A Ehlers; Sh Kim; Y Zhang; R T Ethridge; C Murrilo; M R Hellmich; D B Evans; C M Townsend; B Mark Evers
Journal:  Ann Surg       Date:  2000-06       Impact factor: 12.969

Review 3.  Pancreatic cancer - a continuing challenge in oncology.

Authors:  Attila Zalatnai
Journal:  Pathol Oncol Res       Date:  2003-12-22       Impact factor: 3.201

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.